{
    "nct_id": "NCT00103649",
    "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",
    "status": "COMPLETED",
    "last_update_time": "2008-08-20",
    "description_brief": "The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).",
    "description_detailed": "N/A",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "xaliproden (SR57746A)"
    ],
    "placebo": [
        "placebo (inactive pill)"
    ],
    "explanation_target": [
        "Reason: The trial tests xaliproden to slow cognitive/global decline in mild\u2013moderate Alzheimer\u2019s disease (intent: alter disease course). The intervention is an orally active, non\u2011peptidic small molecule with reported neurotrophic/neuroprotective activity rather than a biologic (monoclonal antibody or vaccine). \ue200cite\ue202turn1search0\ue202turn1search7\ue201",
        "Act: Xaliproden (SR57746A) is described in preclinical and review literature as a non\u2011peptidic, orally active compound with 5\u2011HT1A agonist\u2013mediated activation of MAPK and neuroprotective/neurotrophic effects; several Phase 3 trials (Sanofi-sponsored, NCT00103649 and related entries) tested it in Alzheimer's disease. Because it is a small molecule aiming at neuroprotection/disease modification, it matches the 'disease-targeted small molecule' category. \ue200cite\ue202turn0search5\ue202turn1search0\ue202turn1search7\ue201",
        "Reflect: The description and literature show xaliproden is not a biologic and was intended to slow deterioration (disease\u2011modifying/neuroprotective mechanism), so 'disease-targeted small molecule' is the appropriate classification. No evidence in the provided description that it is solely a symptomatic cognitive enhancer or a neuropsychiatric\u2011symptom treatment. \ue200cite\ue202turn1search7\ue202turn1search0\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: Xaliproden (SR57746A) is a small, orally active compound whose pharmacology is primarily as a 5\u2011HT1A (serotonin) receptor agonist that produces neurotrophic/neuroprotective effects via activation of MAPK/ERK and related signaling pathways; the immediate molecular target is a neurotransmitter GPCR (5\u2011HT1A). \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: The trial description and registry entries show the Phase\u20113 study tested xaliproden to slow cognitive/global decline in mild\u2011to\u2011moderate Alzheimer\u2019s disease, i.e., a disease\u2011modifying/neuroprotective intent. Because the drug acts principally at a neurotransmitter receptor (5\u2011HT1A), the correct CADRO category is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search5\ue202turn0search7\ue201",
        "Reflect: Alternative interpretations (e.g., classifying by downstream MAPK/neurotrophic signaling) were considered, but CADRO is organized by proximal molecular/biologic targets; the proximal target here is a serotonin (5\u2011HT1A) receptor, which maps to Neurotransmitter Receptors rather than Growth Factors, Proteostasis, or multi\u2011target. No evidence in the provided description indicates primary targeting of amyloid, tau, inflammation, vasculature, or other CADRO categories. \ue200cite\ue202turn0search6\ue202turn0search1\ue201",
        "Evidence (selected web sources supporting mechanism and trial intent):",
        "- PubMed: \"Xaliproden (SR57746A) induces 5\u2011HT1A receptor\u2011mediated MAP kinase activation in PC12 cells\" (describes 5\u2011HT1A agonist activity and MAPK/ERK activation). \ue200cite\ue202turn0search0\ue201",
        "- PubMed: \"MAPK activation via 5\u2011hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden\" (neuroprotective effects mediated by 5\u2011HT1A \u2192 MAPK). \ue200cite\ue202turn0search1\ue201",
        "- British Journal of Pharmacology review: describes xaliproden as a selective/potent 5\u2011HT1A receptor agonist with pro\u2011neurotrophic properties. \ue200cite\ue202turn0search6\ue201",
        "- Clinical trial registry entries (NCT00103649 and related listings) describing the 18\u2011month Phase\u20113 study of xaliproden to slow cognitive/global decline in mild\u2011to\u2011moderate Alzheimer\u2019s disease (Sanofi). \ue200cite\ue202turn0search5\ue202turn0search7\ue201"
    ]
}